Please ensure Javascript is enabled for purposes of website accessibility

Accuray Reports Solid Earnings in its Second Fiscal Quarter

By Brian Orelli, PhD - Jan 28, 2020 at 5:45PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Management sees revenue growing faster in the second half of the fiscal year.

Shares of Accuray (ARAY -2.97%), which sells radiosurgery and radiation therapy systems for treating cancer, were up 13% at 4:57 p.m. EST in after hours trading after the company reported better-than-expected fiscal second quarter results. Management noted that the company expects revenue growth to improve in the second half of fiscal 2020.

Gross orders of the company's systems totaled $98.6 million, a little less than the $100.2 million in the year-ago quarter. But net orders came in at $89.9 million, up 30% year-over-year as the backlog at the end of the quarter increased 12% to $539.4 million.

There were 11 orders from China during the quarter, highlighting the company's strategy to go after sales in the world's fastest growing market for radiation oncology systems.

Radixact system

Radixact system. Image source: Accuray

The healthcare company turned a profit in the quarter, but that was entirely due to a non-cash, special gain of $13 million related to its joint venture in China. Backing out the gain, the company would have lost $2.3 million, which would still be better than the $4.6 million loss Accuray registered in the year-ago quarter.

Management expects revenue of $410 million to $420 million for the year, suggesting sales will grow faster in the second half of fiscal 2020 in part because the company will be able to start recognizing revenue from China Type A systems starting in the fourth fiscal quarter. Accuray has confirmed that the trade war between the U.S. and China won't affect the company because all of its systems qualify for China's tariff exemption for medical linear accelerators.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Accuray Incorporated Stock Quote
Accuray Incorporated
ARAY
$1.96 (-2.97%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.